vs
Side-by-side financial comparison of Sachem Capital Corp. (SACH) and Spero Therapeutics, Inc. (SPRO). Click either name above to swap in a different company.
Spero Therapeutics, Inc. is the larger business by last-quarter revenue ($12.6M vs $12.0M, roughly 1.0× Sachem Capital Corp.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs 8.3%, a 242.4% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs -18.8%). Over the past eight quarters, Spero Therapeutics, Inc.'s revenue compounded faster (847.7% CAGR vs -13.4%).
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
SACH vs SPRO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $12.6M |
| Net Profit | $997.0K | $31.5M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | — |
| Net Margin | 8.3% | 250.7% |
| Revenue YoY | -18.8% | 24080.8% |
| Net Profit YoY | 119.7% | 250.9% |
| EPS (diluted) | $0.00 | $0.56 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.6M | ||
| Q3 25 | $12.0M | $0 | ||
| Q2 25 | $10.8M | $0 | ||
| Q1 25 | $11.4M | $12.0K | ||
| Q4 24 | $10.8M | $52.0K | ||
| Q3 24 | $14.8M | $65.0K | ||
| Q2 24 | $15.1M | $114.0K | ||
| Q1 24 | $16.8M | $140.0K |
| Q4 25 | — | $31.5M | ||
| Q3 25 | $997.0K | $-7.4M | ||
| Q2 25 | $1.9M | $-1.7M | ||
| Q1 25 | $904.0K | $-13.9M | ||
| Q4 24 | $-36.1M | — | ||
| Q3 24 | $-5.1M | $-17.1M | ||
| Q2 24 | $-3.1M | $-17.9M | ||
| Q1 24 | $4.7M | $-12.7M |
| Q4 25 | — | — | ||
| Q3 25 | -3.1% | — | ||
| Q2 25 | 9.9% | — | ||
| Q1 25 | 9.0% | -122758.3% | ||
| Q4 24 | -131.1% | — | ||
| Q3 24 | -32.6% | -28604.6% | ||
| Q2 24 | -20.6% | -16720.2% | ||
| Q1 24 | 25.4% | -9987.1% |
| Q4 25 | — | 250.7% | ||
| Q3 25 | 8.3% | — | ||
| Q2 25 | 17.5% | — | ||
| Q1 25 | 7.9% | -115550.0% | ||
| Q4 24 | -335.6% | — | ||
| Q3 24 | -34.2% | -26380.0% | ||
| Q2 24 | -20.2% | -15668.4% | ||
| Q1 24 | 27.8% | -9049.3% |
| Q4 25 | — | $0.56 | ||
| Q3 25 | $0.00 | $-0.13 | ||
| Q2 25 | $0.02 | $-0.03 | ||
| Q1 25 | $0.00 | $-0.25 | ||
| Q4 24 | $-0.79 | — | ||
| Q3 24 | $-0.13 | $-0.32 | ||
| Q2 24 | $-0.09 | $-0.33 | ||
| Q1 24 | $0.08 | $-0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.6M | $40.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $175.6M | $59.0M |
| Total Assets | $484.4M | $68.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.3M | ||
| Q3 25 | $12.6M | $48.6M | ||
| Q2 25 | $23.5M | $31.2M | ||
| Q1 25 | $25.8M | $48.9M | ||
| Q4 24 | $19.6M | $52.9M | ||
| Q3 24 | $7.4M | $76.3M | ||
| Q2 24 | $12.4M | $63.5M | ||
| Q1 24 | $56.8M | $82.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $230.2M | — | ||
| Q4 24 | $230.2M | — | ||
| Q3 24 | $264.7M | — | ||
| Q2 24 | $264.7M | — | ||
| Q1 24 | $288.4M | — |
| Q4 25 | — | $59.0M | ||
| Q3 25 | $175.6M | $26.5M | ||
| Q2 25 | $177.9M | $32.8M | ||
| Q1 25 | $179.3M | $33.8M | ||
| Q4 24 | $181.7M | $46.1M | ||
| Q3 24 | $220.6M | $65.5M | ||
| Q2 24 | $230.2M | $80.5M | ||
| Q1 24 | $237.4M | $96.2M |
| Q4 25 | — | $68.9M | ||
| Q3 25 | $484.4M | $54.2M | ||
| Q2 25 | $501.8M | $62.1M | ||
| Q1 25 | $491.4M | $77.7M | ||
| Q4 24 | $492.0M | $110.5M | ||
| Q3 24 | $555.5M | $135.2M | ||
| Q2 24 | $586.3M | $149.9M | ||
| Q1 24 | $626.5M | $167.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.28× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.15× | — | ||
| Q1 24 | 1.21× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.9M | $-8.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 4.95× | -0.26× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.4M | ||
| Q3 25 | $4.9M | $17.4M | ||
| Q2 25 | $501.0K | $-17.7M | ||
| Q1 25 | $191.0K | $-4.0M | ||
| Q4 24 | $12.9M | $-23.4M | ||
| Q3 24 | $2.3M | $12.8M | ||
| Q2 24 | $7.0M | $-18.7M | ||
| Q1 24 | $4.2M | $5.9M |
| Q4 25 | — | -0.26× | ||
| Q3 25 | 4.95× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.90× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
